{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T07:05:51Z","timestamp":1790406351926,"version":"4.1.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2005,8,9]],"date-time":"2005-08-09T00:00:00Z","timestamp":1123545600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2005,10]]},"DOI":"10.1245\/aso.2005.03.023","type":"journal-article","created":{"date-parts":[[2005,8,12]],"date-time":"2005-08-12T07:35:12Z","timestamp":1123832112000},"page":"825-830","source":"Crossref","is-referenced-by-count":48,"title":["TNFerade, an Adenovector Carrying the Transgene for Human Tumor Necrosis Factor \u03b1, for Patients With Advanced Solid Tumors: Surgical Experience and Long-Term Follow-Up"],"prefix":"10.1245","volume":"12","author":[{"given":"James M.","family":"McLoughlin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd M.","family":"McCarty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Casey","family":"Cunningham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Senzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Nemunaitis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph A.","family":"Kuhn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2005,8,9]]},"reference":[{"key":"7090_CR1","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.1073\/pnas.72.9.3666","volume":"72","author":"EA Carswell","year":"1975","unstructured":"Carswell EA, Old LJ, Kassel RL, et al. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A 1975;72:3666\u201370","journal-title":"Proc Natl Acad Sci U S A"},{"key":"7090_CR2","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1200\/JCO.1988.6.8.1328","volume":"6","author":"B Feinberg","year":"1988","unstructured":"Feinberg B, Kurzrock R, Talpaz M, et al. A phase I trial of intravenously-administered recombinant tumor necrosis factor-alpha in cancer patients. J Clin Oncol 1988;6:1328\u201334","journal-title":"J Clin Oncol"},{"key":"7090_CR3","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1128\/iai.30.2.523-530.1980","volume":"30","author":"DN Mannel","year":"1980","unstructured":"Mannel DN, Moore RN, Mergenhagen SE. Macrophages as a source of tumoricidal activity (tumor-necrotizing factor). Infect Immun 1980;30:523\u201330","journal-title":"Infect Immun"},{"key":"7090_CR4","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1096\/fasebj.4.14.2172061","volume":"4","author":"JW Larrick","year":"1990","unstructured":"Larrick JW, Wright SC. Cytotoxic mechanism of tumor necrosis factor-alpha. FASEB J 1990;4:3215\u201323","journal-title":"FASEB J"},{"key":"7090_CR5","doi-asserted-by":"crossref","first-page":"963","DOI":"10.4049\/jimmunol.138.3.963","volume":"138","author":"A Asher","year":"1987","unstructured":"Asher A, Mule JJ, Reichert CM, et al. Studies on the anti-tumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo. J Immunol 1987;138:963\u201374","journal-title":"J Immunol"},{"key":"7090_CR6","doi-asserted-by":"crossref","first-page":"5161","DOI":"10.4049\/jimmunol.169.9.5161","volume":"169","author":"AE Tcherkasowa","year":"2002","unstructured":"Tcherkasowa AE, Adam-Klages S, Kruse ML, et al. Interaction with factor associated with neutral sphingomyelinase activation, a WD motif-containing protein, identifies receptor for activated C-kinase 1 as a novel component of the signaling pathways of the p55 TNF receptor. J Immunol 2002;169:5161\u201370","journal-title":"J Immunol"},{"key":"7090_CR7","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1146\/annurev.immunol.17.1.331","volume":"17","author":"D Wallach","year":"1999","unstructured":"Wallach D, Varfolomeev EE, Malinin NL, et al. Tumor necrosis factor receptor and Fas signaling mechanisms. Ann Rev Immunol 1999;17:331\u201367","journal-title":"Ann Rev Immunol"},{"key":"7090_CR8","doi-asserted-by":"crossref","first-page":"5916","DOI":"10.1074\/jbc.273.10.5916","volume":"273","author":"R Schwandner","year":"1998","unstructured":"Schwandner R, Wiegmann K, Bernardo K, et al. TNF receptor death domain-associated proteins TRADD and FADD signal activation of acid sphingomyelinase. J Biol Chem 1998;273:5916\u201322","journal-title":"J Biol Chem"},{"key":"7090_CR9","first-page":"2713","volume":"61","author":"G Kulik","year":"2001","unstructured":"Kulik G, Carson JP, Vomastek T, et al. Tumor necrosis factor alpha induces BID cleavage and bypasses antiapoptotic signals in prostate cancer LNCaP cells. Cancer Res 2001;61:2713\u20139","journal-title":"Cancer Res"},{"key":"7090_CR10","doi-asserted-by":"crossref","first-page":"8610","DOI":"10.1074\/jbc.275.12.8610","volume":"275","author":"K Kimura","year":"2000","unstructured":"Kimura K, Gelmann EP. Tumor necrosis factor-alpha and Fas activate complementary Fas-associated death domain-dependent pathways that enhance apoptosis induced by gamma-irradiation. J Biol Chem 2000;275:8610\u20137","journal-title":"J Biol Chem"},{"key":"7090_CR11","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S0962-8924(01)02064-5","volume":"11","author":"V Baud","year":"2001","unstructured":"Baud V, Karin M. Signal transduction by tumor necrosis factor and its relatives. Trends Cell Biol 2001;11:372\u20137","journal-title":"Trends Cell Biol"},{"key":"7090_CR12","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S0968-0004(97)01107-9","volume":"22","author":"P Villa","year":"1997","unstructured":"Villa P, Kaufmann SH, Earnshaw WC. Caspases and caspase inhibitors. Trends Biochem Sci 1997;22:388\u201393","journal-title":"Trends Biochem Sci"},{"key":"7090_CR13","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1084\/jem.185.3.481","volume":"185","author":"GS Dbaibo","year":"1997","unstructured":"Dbaibo GS, Perry DK, Gamard CJ, et al. Cytokine response modifier A (CrmA) inhibits ceramide formation in response to tumor necrosis factor (TNF)-alpha: CrmA and Bcl-2 target distinct components in the apoptotic pathway. J Exp Med 1997;185:481\u201390","journal-title":"J Exp Med"},{"key":"7090_CR14","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/0092-8674(94)90275-5","volume":"78","author":"K Wiegmann","year":"1994","unstructured":"Wiegmann K, Schutze S, Machleidt T, et al. Functional dichotomy of neutral and acidic sphingomyelinases in tumor necrosis factor signaling. Cell 1994;78:1005\u201315","journal-title":"Cell"},{"key":"7090_CR15","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/25248","volume":"396","author":"DR Green","year":"1998","unstructured":"Green DR. Apoptosis. Death deceiver (comment). Nature 1998;396:629\u201330","journal-title":"Nature"},{"key":"7090_CR16","first-page":"4311","volume":"56","author":"HJ Mauceri","year":"1996","unstructured":"Mauceri HJ, Hanna NN, Wayne JD, et al. Tumor necrosis factor alpha (TNF-alpha) gene therapy targeted by ionizing radiation selectively damages tumor vasculature. Cancer Res 1996;56:4311\u20134","journal-title":"Cancer Res"},{"key":"7090_CR17","first-page":"5537","volume":"50","author":"V Mahadevan","year":"1990","unstructured":"Mahadevan V, Malik ST, Meager A, et al. Role of tumor necrosis factor in flavone acetic acid-induced tumor vasculature shutdown. Cancer Res 1990;50:5537\u201342","journal-title":"Cancer Res"},{"key":"7090_CR18","first-page":"4824","volume":"55","author":"D Fukumura","year":"1995","unstructured":"Fukumura D, Salehi HA, Witwer B, et al. Tumor necrosis factor alpha-induced leukocyte adhesion in normal and tumor vessels: effect of tumor type, transplantation site, and host strain. Cancer Res 1995;55:4824\u20139","journal-title":"Cancer Res"},{"key":"7090_CR19","first-page":"3990","volume":"46","author":"FR Balkwill","year":"1986","unstructured":"Balkwill FR, Lee A, Aldam G, et al. Human tumor xenografts treated with recombinant human tumor necrosis factor alone or in combination with interferons. Cancer Res 1986;46:3990\u20133","journal-title":"Cancer Res"},{"key":"7090_CR20","doi-asserted-by":"crossref","first-page":"11137","DOI":"10.1073\/pnas.90.23.11137","volume":"90","author":"EI Korpelainen","year":"1993","unstructured":"Korpelainen EI, Gamble JR, Smith WB, et al. The receptor for interleukin 3 is selectively induced in human endothelial cells by tumor necrosis factor alpha and potentiates interleukin 8 secretion and neutrophil transmigration. Proc Natl Acad Sci U S A 1993;90:11137\u201341","journal-title":"Proc Natl Acad Sci U S A"},{"key":"7090_CR21","doi-asserted-by":"crossref","first-page":"333","DOI":"10.4049\/jimmunol.153.1.333","volume":"153","author":"AM Pilaro","year":"1994","unstructured":"Pilaro AM, Taub DD, McCormick KL, et al. TNF-alpha is a principal cytokine involved in the recruitment of NK cells to liver parenchyma. J Immunol 1994;153:333\u201342","journal-title":"J Immunol"},{"key":"7090_CR22","first-page":"5561","volume":"55","author":"LP Seung","year":"1995","unstructured":"Seung LP, Mauceri HJ, Beckett MA, et al. Genetic radiotherapy overcomes tumor resistance to cytotoxic agents. Cancer Res 1995;55:5561\u20135","journal-title":"Cancer Res"},{"key":"7090_CR23","doi-asserted-by":"crossref","first-page":"10104","DOI":"10.1073\/pnas.86.24.10104","volume":"86","author":"DE Hallahan","year":"1989","unstructured":"Hallahan DE, Spriggs DR, Beckett MA, et al. Increased tumor necrosis factor alpha mRNA after cellular exposure to ionizing radiation. Proc Natl Acad Sci U S A 1989;86:10104\u20137","journal-title":"Proc Natl Acad Sci U S A"},{"key":"7090_CR24","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1126\/science.3933111","volume":"230","author":"BJ Sugarman","year":"1985","unstructured":"Sugarman BJ, Aggarwal BB, Hass PE, et al. Recombinant human tumor necrosis factor-alpha: effects on proliferation of normal and transformed cells in vitro. Science 1985;230:943\u20135","journal-title":"Science"},{"key":"7090_CR25","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/0277-5379(86)90107-0","volume":"22","author":"L Fransen","year":"1986","unstructured":"Fransen L, Van der Heyden J, Ruysschaert R, Fiers W. Recombinant tumor necrosis factor: its effect and its synergism with interferon-gamma on a variety of normal and transformed human cell lines. Eur J Cancer Clin Oncol 1986;22:419\u201326","journal-title":"Eur J Cancer Clin Oncol"},{"key":"7090_CR26","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1200\/JCO.1987.5.12.1942","volume":"5","author":"PB Chapman","year":"1987","unstructured":"Chapman PB, Lester TJ, Casper ES, et al. Clinical pharmacology of recombinant human tumor necrosis factor in patients with advanced cancer. J Clin Oncol 1987;5:1942\u201351","journal-title":"J Clin Oncol"},{"key":"7090_CR27","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1093\/jnci\/80.13.1039","volume":"80","author":"DR Spriggs","year":"1988","unstructured":"Spriggs DR, Sherman ML, Michie H, et al. Recombinant human tumor necrosis factor administered as a 24-hour intravenous infusion. A phase I and pharmacologic study. J Natl Cancer Inst 1988;80:1039\u201344","journal-title":"J Natl Cancer Inst"},{"key":"7090_CR28","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1159\/000227329","volume":"51","author":"U Hieber","year":"1994","unstructured":"Hieber U, Heim ME. Tumor necrosis factor for the treatment of malignancies. Oncology 1994;51:142\u201353","journal-title":"Oncology"},{"key":"7090_CR29","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1200\/JCO.1992.10.1.52","volume":"10","author":"D Lienard","year":"1992","unstructured":"Lienard D, Ewalenko P, Delmotte JJ, et al. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 1992;10:52\u201360","journal-title":"J Clin Oncol"},{"key":"7090_CR30","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1200\/JCO.1995.13.1.264","volume":"13","author":"AK Thom","year":"1995","unstructured":"Thom AK, Alexander HR, Andrich MP, et al. Cytokine levels and systemic toxicity in patients undergoing isolated limb perfusion with high-dose tumor necrosis factor, interferon gamma, and melphalan. J Clin Oncol 1995;13:264\u201373","journal-title":"J Clin Oncol"},{"key":"7090_CR31","first-page":"62","volume-title":"Biologic Therapy of Cancer, Fourth Edition. Philadelphia: Lippincott","author":"D Fraker","year":"1994","unstructured":"Fraker D, Alexander H, Pass H. Biologic therapy with TNF systemic and regional administration. In: DeVita VT, Jr, Hellman S, Rosenberg SA, eds. Biologic Therapy of Cancer. Philadelphia: Lippincott, 1994:62\u20139."},{"key":"7090_CR32","first-page":"509","volume":"12","author":"RA Marr","year":"1998","unstructured":"Marr RA, Hitt M, Muller WJ, et al. Tumour therapy in mice using adenovirus vectors expressing human TNFa. Int J Oncol 1998;12:509\u201315","journal-title":"Int J Oncol"},{"key":"7090_CR33","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1038\/sj.cgt.7700518","volume":"9","author":"H Rasmussen","year":"2002","unstructured":"Rasmussen H, Rasmussen C, Lempicki M, et al. TNFerade biologic: preclinical toxicology of a novel adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene. Cancer Gene Ther 2002;9:951\u20137","journal-title":"Cancer Gene Ther"},{"key":"7090_CR34","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1200\/JCO.2004.01.227","volume":"22","author":"N Senzer","year":"2004","unstructured":"Senzer N, Mani S, Rosemurgy A, et al. TNFerade biologic, an adenovector with radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors. J Clin Oncol 2004;22:592\u2013601","journal-title":"J Clin Oncol"},{"key":"7090_CR35","doi-asserted-by":"crossref","first-page":"5747","DOI":"10.1158\/1078-0432.CCR-04-0296","volume":"10","author":"AJ Mundt","year":"2004","unstructured":"Mundt AJ, Vijayakumar S, Nemunaitis J, et al. A phase I trial of TNFerade biologic in patients with soft tissue sarcoma in the extremities. Clin Cancer Res 2004;10:5747\u201353.","journal-title":"Clin Cancer Res"},{"key":"7090_CR36","doi-asserted-by":"crossref","first-page":"10149","DOI":"10.1073\/pnas.89.21.10149","volume":"89","author":"R Datta","year":"1992","unstructured":"Datta R, Rubin E, Sukhatme V, et al. Ionizing radiation activates transcription of the EGR1 gene via CArG elements. Proc Natl Acad Sci U S A 1992;89:10149\u201353","journal-title":"Proc Natl Acad Sci U S A"},{"key":"7090_CR37","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1634\/theoncologist.7-1-46","volume":"7","author":"SA Vorburger","year":"2002","unstructured":"Vorburger SA, Hunt KK. Adenoviral gene therapy. Oncologist 2002;7:46\u201359","journal-title":"Oncologist"},{"key":"7090_CR38","doi-asserted-by":"crossref","first-page":"6497","DOI":"10.1128\/JVI.70.9.6497-6501.1996","volume":"70","author":"DE Brough","year":"1996","unstructured":"Brough DE, Lizonova A, Hsu C, et al. A gene transfer vector-cell line system for complete functional complementation of adenovirus early regions E1 and E4. J Virol 1996;70:6497\u2013501","journal-title":"J Virol"},{"key":"7090_CR39","first-page":"137","volume":"20","author":"PJ Creaven","year":"1987","unstructured":"Creaven PJ, Plager JE, Dupere S, et al. Phase I clinical trial of recombinant human tumor necrosis factor. Cancer Chemother Pharmacol 1987;20:137\u201344","journal-title":"Cancer Chemother Pharmacol"},{"key":"7090_CR40","first-page":"544","volume":"48","author":"JE Talmadge","year":"1988","unstructured":"Talmadge JE, Phillips H, Schneider M, et al. Immunomodulatory properties of recombinant murine and human tumor necrosis factor. Cancer Res 1988;48:544\u201350","journal-title":"Cancer Res"},{"key":"7090_CR41","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1159\/000420682","volume":"50","author":"JP Johnson","year":"1991","unstructured":"Johnson JP. The role of ICAM-1 in tumor development. Chem Immunol 1991;50:143\u201363","journal-title":"Chem Immunol"},{"key":"7090_CR42","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.4049\/jimmunol.141.8.2629","volume":"141","author":"SM Laster","year":"1988","unstructured":"Laster SM, Wood JG, Gooding LR. Tumor necrosis factor can induce both apoptotic and necrotic forms of cell lysis. J Immunol 1988;141:2629\u201334","journal-title":"J Immunol"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/ASO.2005.03.023.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1245\/ASO.2005.03.023\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/ASO.2005.03.023","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T04:28:47Z","timestamp":1683174527000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1245\/ASO.2005.03.023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,8,9]]},"references-count":42,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2005,10]]}},"alternative-id":["7090"],"URL":"https:\/\/doi.org\/10.1245\/aso.2005.03.023","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,8,9]]}}}